Related Experiment Video
Updated: Jun 10, 2026
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
[Detecting EGFR autoantibodies in serums of NSCLC patients with peptide array]
Yuan Li1, Wentao Yue, Yue Wang
1Department of Cellular and Molecular Biology, Beijing TB and Thoracic Tumor Research Institute, Beijing 101149, China.
Background And Objective:
Autoantibodies as new tumor markers may play an important role in the early diagnosis and evaluating the prognosis of lung cancer. In this study, we detect epidermal growth factor receptor (EGFR) autoantibodies using peptide array and screen the epitopes which are recognized by EGFR autoantibodies.
Methods:
Peptide array covering the extracellular domain of EGFR protein was synthesized by a synthesizer (ASPSL) made by Intavis company. EGFR autoantibodies in the serums of non-small cell lung cancer patients was detected using peptide array.
Results:
Six of 20 patients were found to have EGFR autoantibodies. The positive rate is 30%. Nine high frequency spots were found in the 6 positive patients and 8 high frequency spots clustered in the III and IV domains.
Conclusions:
These findings will offer new clues for the further studies of EGFR and EGFR autoantibodies.
